SUPPLEMENTARY METHODS

Data collection procedures
All data from Necker and Toulouse Hospitals regarding donor and recipient were extracted 
Independent validation cohort
This external validation set is composed of the 4128 consecutive kidney recipients transplanted in Lyon, Montpellier, Nancy, and Nantes hospitals, France. Kidney transplantations were performed between 1 January, 2002 and 31 December, 2011. Similar immunological rules for kidney transplantation applied, with all transplantations being ABO compatible with a negative current IgG T-cell and B-cell complement-dependent cytotoxicity cross-matching required for all patients. The quantification of day-0 anti-HLA sensitisation was determined in the validation cohort using cytotoxic panel-reactive antibodies (PRAs) for the patients transplanted before July 2009 and calculated PRAs (cPRAs) for the kidney recipient patients transplanted after July 2009. A PRA value >5% was defined as the threshold for defining sensitised patients according to the French national agency for organ procurement recommendations (Agence de la biomedicine (http://www.sipg.sante.fr/portail/)).
Post-transplantation induction protocols and maintenance of immunosuppressive therapy
Patients received induction therapy consisting of rabbit antithymocytes globulin (1.5 mg per kilogram per day, for 10 days) or basiliximab (20 mg at day 0 and day 4) immediately after transplantation. Subsequent maintenance immunosuppressive therapy consisted of prednisone, mycophenolate mofetil (1000 mg twice daily), tacrolimus administrated to maintain a target blood level of 8 to 10 ng per millilitre for the first 3 months and 6 to 8 ng per milliliter after 3 months or cyclosporine administrated to maintain a target blood level of 800 to 1200 ng per millilitre for the first 3 months and 600 to 800 ng per milliliter after 3 months.
Kidney allograft lesions: Banff scoring system (15)
Chronicity scores reflecting donor-derived lesions and baseline transplant damage were measured in preimplantation biopsies according to the percentage of sclerotic glomeruli, interstitial fibrosis/tubular atrophy (IF/TA score), arteriolar hyaline thickening (ah score) and vascular fibrous intimal thickening arteriosclerosis (cv score). In addition, the following histological factors were assessed and scored in all post-transplant kidney allograft biopsies:
glomerulitis (g score), tubulitis (t score), mononuclear cell interstitial inflammation (i score), intimal arteritis (v score), peritubular capillaritis (ptc score), and allograft glomerulopathy (cg score). C4d staining was performed in the post-transplant biopsies by immunochemistry on paraffin sections using polyclonal human anti-C4d antibodies (Biomedica Gruppe, Austria).
Propensity score
To test whether older recipient age might have affected allograft outcome and the associations identified in the primary analyses, a propensity score was used, which estimates the a posteriori probability of assigning an ECD kidney conditional on baseline ECD recipients matched with 540 SCD recipients. The mean recipient age was 55±10 years in the ECD group and 54±9 years in the SCD group.
KDRI score
The KDRI score included the following: 
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